{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055652","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.440327+00:00","generated_at":"2026-06-02T10:38:53.075072+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alector Q1 net loss $36.1M ($0.38/share); cash runway through 2026","bullets":["Q1 net loss $36.1M ($0.38/share) vs $45.9M ($0.55) in Q1 2023.","Collaboration revenue $15.9M, roughly flat vs $16.5M year ago.","Cash, equivalents & investments $562.1M; expects runway through 2026.","INVOKE-2 Phase 2 TREM2 data for early Alzheimer's expected Q4 2024; INFRONT-3 Phase 3 latozinemab fully enrolled.","Neil Berkley named CBO; Errol De Souza and Mark Altmeyer join Board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055652","json":"https://secwatch.observer/filing/0000950170-24-055652.json","markdown":"https://secwatch.observer/filing/0000950170-24-055652.md","text":"https://secwatch.observer/filing/0000950170-24-055652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017024055652/0000950170-24-055652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017024055652/alec-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:38:53.075072+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a6161dc5e3943f5e39a63b1790a0bcf7613af87","claim":"Alector, Inc. reported financial results for First Quarter 2024.","evidence_excerpt":"Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1653087/000095017024055652/0000950170-24-055652-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First Quarter 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}